EGFR and colorectal carcinoma: Therefore, it provides a rationale that the CRC patients harboring activating mutations in KRAS (~45%) or NRAS (~5%), which function as a strong inducer of these signaling cascades irrespective of EGFR, are refractory to both cetuximab and panitumumab directed therapy [10,11,12,13,14].